Difference between revisions of "Part:BBa K2309022:Experience"
Zixin.Rong (Talk | contribs) |
Zixin.Rong (Talk | contribs) (→Applications of BBa_K2309022) |
||
| Line 4: | Line 4: | ||
===Applications of BBa_K2309022=== | ===Applications of BBa_K2309022=== | ||
This year we use dot blot method to evaluate part K2309022 work. | This year we use dot blot method to evaluate part K2309022 work. | ||
| − | |||
The picture shows the dot blotting result of produced LL-37 which induced by IPTG in BL21 strain. The left one shows the peptide produced and right is negative contral group. | The picture shows the dot blotting result of produced LL-37 which induced by IPTG in BL21 strain. The left one shows the peptide produced and right is negative contral group. | ||
| + | |||
| + | https://static.igem.org/mediawiki/parts/8/82/Dot_blot_for_LL-37_XJTLU-CHINA.jpeg | ||
| + | |||
===User Reviews=== | ===User Reviews=== | ||
<!-- DON'T DELETE --><partinfo>BBa_K2309022 StartReviews</partinfo> | <!-- DON'T DELETE --><partinfo>BBa_K2309022 StartReviews</partinfo> | ||
Revision as of 08:43, 27 October 2017
Applications of BBa_K2309022
This year we use dot blot method to evaluate part K2309022 work. The picture shows the dot blotting result of produced LL-37 which induced by IPTG in BL21 strain. The left one shows the peptide produced and right is negative contral group.
User Reviews
UNIQab218094a02189da-partinfo-00000000-QINU UNIQab218094a02189da-partinfo-00000001-QINU